Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CFC-free inhalers

Executive Summary

GlaxoSmithKline is urging FDA and the Office of Management & Budget to issue final rule on ozone-depleting substances. The proposed rule, issued in September 1999, laid out FDA's suggested approach to phasing out metered dose inhalers that contain chlorofluorocarbons (1"The Pink Sheet" Sept. 9, 1999, p. 3). GSK met June 3 with representatives from OMB, Center for Drug Evaluation & Research Associate Director-Policy Jane Axelrad and Office of Drug Evaluation II Director Robert Meyer, MD, to discuss expediting the rule. The company launched the CFC-free inhaler Ventolin HFA (albuterol) in February, and is phasing out its CFC-containing Ventolin product...

You may also be interested in...



CFC-Containing MDIs Are "Essential" Until Multiple Alternatives Available

More than one CFC-free product alternative must be available before FDA phases out a CFC-containing metered dose inhaler that is available under multiple NDAs or in multiple strengths, the agency suggests in a proposed rule on ozone depleting substances (ODS) published in the Sept. 1 Federal Register.

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel